A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication
Phase of Trial: Phase II
Latest Information Update: 25 Mar 2017
At a glance
- Drugs Evenamide (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Newron Pharmaceuticals
- 25 Mar 2017 Results presented at the 16th International Congress on Schizophrenia Research 2017, according to a Newron Pharmaceuticals media release.
- 25 Mar 2017 Results published in a Newron Pharmaceuticals media release.
- 13 Mar 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History